Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
China Isotope & Radiation Corp. ( (HK:1763) ) has shared an update.
China Isotope & Radiation Corporation announced that its subsidiary, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., has been recognized as a National-Level Manufacturing Enterprise and awarded the ‘Single-Item Champion in the Pharmaceutical Industry’ for its Urea [13C/14C] Breath Test Kits. This accolade underscores CIRC’s leading position in the breath diagnostic sector and its commitment to innovation and expanding its product offerings to enhance national health defenses.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
More about China Isotope & Radiation Corp.
China Isotope & Radiation Corporation (CIRC) operates in the pharmaceutical industry, focusing on medical isotope applications. Its primary products include urea [13C] and [14C] breath diagnostic kits, used to detect Helicobacter pylori. The company has a significant market presence, serving over 20,000 customers in China and exporting to 90 countries.
Average Trading Volume: 254,458
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.19B
See more data about 1763 stock on TipRanks’ Stock Analysis page.